NBE-Therapeutics, a Basel, Switzerland-based biotech company, closed a CHF20M Series B funding.
The round was led by PPF Group with participation from Boehringer Ingelheim Venture Fund, other existing investors and a new private investor. In conjunction with the funding, Dr. Jens Hennecke, CBO of SOTIO a.s., an international biotechnology company developing therapies for the treatment of cancer, joined the board of directors of NBE.
The company intends to use the funds to advance the lead product of its ADC pipeline to the end of phase I/II clinical trials and to further develop its platforms.
Founded in 2012 and led by Dr. Ulf Grawunder, CEO, NBE Therapeutics develops Antibody-Drug Conjugate (ADC) products with the potential to improve the outcome for cancer patients. The company leverages proprietary platforms covering all aspects of ADC development:
– Transpo-mAb DisplayTM technology for antibody discovery,
– patent pending SMAC-TechnologyTM for site-specific payload conjugation of toxins to antibodies, and
– a novel ultra-potent anthracycline-based toxin platform.